OAO has partnered with Sanofi to implement an AI-first enterprise approach using a multi-agent system architecture that systematically identifies and validates AI use cases across all organizational functions. The platform has generated over 1,300 AI use cases across Sanofi's operations, supporting faster model development and delivering measurable commercial uplift.
The multi-agent system captures insights across all levels of the organization, where employees contribute to discovery and innovation. By embedding AI into the fabric of Sanofi's R&D, manufacturing, and commercial operations, OAO and Sanofi are building an enterprise where AI augments every function rather than existing as a standalone tool.
OAO and Sanofi are part of the World Economic Forum's MINDS (Meaningful, Intelligent, Novel, Deployable Solutions) second cohort, selected for demonstrating how AI can deliver measurable impact while ensuring sustainability, inclusivity, and operational resilience. The second cohort brings together 15 additional global industry cases, with the first cohort of 18 unveiled at the Annual Meeting of New Champions 2025 in Hangzhou, China. Collectively, MINDS companies report double-digit gains in productivity and revenue, driven by improved operational efficiency and the ability to scale AI from pilots to enterprise-wide adoption.
Details
- City
- Paris
- Organization
- Sanofi
- Continent
- Europe
- Country
- France
- Category
- Pharmaceuticals
- Type
- Deployment
- Id